LENZ Therapeutics today unveiled its national “Make it VIZZable” consumer campaign, partnering with award-winning actor and producer Sarah Jessica Parker as brand ambassador for VIZZ™ (aceclidine ophthalmic solution) 1.44%. The initiative features Parker sharing her personal journey with age-related blurry near vision, demonstrating how a once-daily instillation of VIZZ eye drops restores clear near vision for up to ten hours and eliminates the need to reach for reading glasses throughout the day.

In the pivotal CLARITY Phase 3 trial, 93% of participants achieved 20/40 or better near vision within thirty minutes of dosing, with effects lasting up to ten hours. The mechanism of action – a predominantly pupil-selective miotic that induces a sub-2mm pupil and extends depth of focus without a myopic shift – was shown to deliver rapid, durable near vision improvement. Adverse events were largely mild and transient, with the most common being instillation site irritation (20%), dim vision (16%), and headache (13%).

Presbyopia affects an estimated 128 million Americans and 1.8 billion people globally, with adults over age 50 losing an average of 1.5 lines of near vision every six years. LENZ is commercializing VIZZ nationwide through eye care professionals and is establishing international licensing partnerships to expand access. The company offers free samples via its online locator tool, aiming to accelerate adoption by demonstrating everyday convenience and freedom from reading glasses.

Seven research firms covering LENZ Therapeutics have issued recommendations, resulting in a consensus “Moderate Buy” rating. Analysts cite the novel mechanism of action, underserved market of presbyopes, and robust Phase 3 data as key drivers. The average twelve-month price target stands at $56.40, reflecting optimism around VIZZ’s commercial rollout and potential to become a standard first-line therapy for age-related blurry near vision.